Provexis plc (FRA:NZCA)

Market Cap	29.09M +71.6%
Revenue (ttm)	998.17K -27.4%
Net Income	-691.75K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0020
Previous Close	0.0025
Day's Range	0.0020 - 0.0020
52-Week Range	0.0005 - 0.0200
Beta	n/a
RSI	45.33
Earnings Date	Sep 10, 2026

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through e-commerce website ...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NZCA

Financial Performance

In fiscal year 2025, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2024.

Financial numbers in GBP